Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chk1i-a
- Development stage
- Preclinical
- Lead developer
- University of Strathclyde
- Modality
- Small Molecules
01
Overview
Chk1i-a is a novel, blood-brain barrier (BBB)-permeable small molecule inhibitor of checkpoint kinase 1 (Chk1) developed by researchers at the University of Strathclyde. It is being investigated for the treatment of glioblastoma (GBM), particularly in combination with temozolomide (TMZ) or Wee1 inhibitors (such as Wee1i-a). In preclinical studies using patient-derived glioblastoma stem-like cells, Chk1i-a demonstrated potent single-agent activity and strong synergistic effects when combined with TMZ, leading to enhanced cell death and reduction in clonogenicity.
- Other names
- Chk1 inhibitor aChk-1 inhibitor aChk 1 inhibitor a
02
Targets
CHEK1 (Checkpoint kinase 1)
Beyond the preview
Go deeper on Chk1i-a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chk1i-a.